Acosta Monica L, Mat Nor Mohd N, Guo Cindy X, Mugisho Odunayo O, Coutinho Frazer P, Rupenthal Ilva D, Green Colin R
School of Optometry and Vision Science; New Zealand National Eye Centre, University of Auckland; Centre for Brain Research, Faculty of Medical and Health Sciences, The University of Auckland; Brain Research New Zealand-Rangahau Roro Aotearoa, Auckland, New Zealand.
School of Optometry and Vision Science, University of Auckland, Auckland, New Zealand; Faculty of Medicine, Universiti Sultan Zainal Abidin, Terengganu, Malaysia.
Neural Regen Res. 2021 Mar;16(3):482-488. doi: 10.4103/1673-5374.290097.
Compounds that block the function of connexin and pannexin protein channels have been suggested to be valuable therapeutics for a range of diseases. Some of these compounds are now in clinical trials, but for many of them, the literature is inconclusive about the molecular effect on the tissue, despite evidence of functional recovery. Blocking the different channel types has distinct physiological and pathological implications and this review describes current knowledge of connexin and pannexin protein channels, their function as channels and possible mechanisms of the channel block effect for the latest therapeutic compounds. We summarize the evidence implicating pannexins and connexins in disease, considering their homeostatic versus pathological roles, their contribution to excesive ATP release linked to disease onset and progression.
已有人提出，能够阻断连接蛋白和泛连接蛋白通道功能的化合物有望成为一系列疾病的有效治疗药物。其中一些化合物目前正处于临床试验阶段，但对于许多此类化合物而言，尽管有功能恢复的证据，但关于其对组织的分子效应，文献尚无定论。阻断不同类型的通道具有不同的生理和病理意义，本综述阐述了目前关于连接蛋白和泛连接蛋白通道的知识，它们作为通道的功能以及最新治疗化合物产生通道阻断效应的可能机制。我们总结了泛连接蛋白和连接蛋白与疾病相关的证据，考量了它们在稳态与病理状态下的作用，以及它们在与疾病发生和进展相关的过量ATP释放中所起的作用。
Zotero 插件